Fennec Announces Pricing of Public Offering
December 08, 2017 08:54 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARKTM (a unique...
Fennec Announces Proposed Public Offering of Common Shares
December 07, 2017 16:01 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...
Fennec Provides Business Update And Reports Third Quarter 2017 Results
November 13, 2017 06:00 ET
|
Fennec Pharmaceuticals Inc.
During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing...
Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
October 16, 2017 06:00 ET
|
Fennec Pharmaceuticals
Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB)Company...
Fennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City
September 20, 2017 08:30 ET
|
Fennec Pharmaceuticals
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals, Inc. (NASDAQ:FENC) (TSX:FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the...
Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) to be Presented at the 49TH Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
September 13, 2017 12:16 ET
|
Fennec Pharmaceuticals
SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protectionAmong the first 94 evaluable...
Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market
September 11, 2017 08:29 ET
|
Fennec Pharmaceuticals
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium...